The overall aim of this study is to review adverse events of decentralized, ambulatory drug-resistant TB (DR-TB) among a high proportion of rifampicin monoresistant TB patients at an outpatient specialized clinic in Johannesburg, South Africa. The study is a retrospective study and differs in two significant ways from previous studies of DR-TB in South Africa. Firstly, a large proportion of the patients receiving decentralized care have rifampicin mono-resistant TB. All the previous studies of DR-TB outcomes have focused on MDR and XDR TB. Secondly, all of the existing studies of MDR-TB outcomes were conducted prior to the rollout of the Gene Xpert MTB/RIF (“Xpert”) assay, which is a replacement for smear microscopy (AFB) in the initial diagnostic evaluation of TB. It is not known if the shift towards Xpert has altered the landscape of DR-TB treatment by allowing for more rapid diagnosis of drug resistance and shorter delay to initiation of appropriate treatment. This study began after the rollout of gene Xpert.
The following publications emanate from this project:
HE2RO staff involvedSydney Rosen Kamban Hirasen Busi Sithole Dr. Ribka Berhanu
Stay up to date
Receive newsletters and keep up to date with developments at HE2RO.